Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedJun 11, 2026
DataAggregated Company Financials
Companies23
  • 7D-2.2%
  • 3M-13.2%
  • 1Y13.5%
  • YTD-10.8%

Over the last 7 days, the Biotech industry has dropped 2.2%, driven by Genus declining 5.5%. In the past year, the industry has gained 13%. As for the next few years, earnings are expected to grow by 22% per annum.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 11 Jun 2026UK£3.2bUK£893.6m-UK£153,180,076.2019.4x-20.8x3.6x
Sat, 09 May 2026UK£3.1bUK£888.4m-UK£111,894,338.9019.3x-27.5x3.5x
Mon, 06 Apr 2026UK£3.1bUK£893.2mUK£3.2m9.2x957.8x3.5x
Wed, 04 Mar 2026UK£3.3bUK£875.5m-UK£4,247,629.168.9x-785.8x3.8x
Fri, 30 Jan 2026UK£3.8bUK£875.9m-UK£29,200,330.7610.9x-131.6x4.4x
Sun, 28 Dec 2025UK£3.2bUK£896.6m-UK£29,559,137.5010.3x-107.9x3.6x
Tue, 25 Nov 2025UK£3.1bUK£895.5m-UK£30,407,958.4010.9x-102.5x3.5x
Thu, 23 Oct 2025UK£3.2bUK£878.9m-UK£44,367,808.0015.8x-72.9x3.7x
Sat, 20 Sep 2025UK£3.4bUK£857.6m-UK£83,268,050.8716.2x-40.5x3.9x
Mon, 18 Aug 2025UK£3.2bUK£854.4m-UK£103,468,659.2811.7x-31.4x3.8x
Wed, 16 Jul 2025UK£2.9bUK£854.7m-UK£103,033,874.9813.1x-27.9x3.4x
Fri, 13 Jun 2025UK£2.6bUK£857.1m-UK£104,218,771.0013.5x-25.2x3.1x
Sun, 11 May 2025UK£2.4bUK£879.5m-UK£95,247,877.4113.2x-25.6x2.8x
Tue, 08 Apr 2025UK£2.1bUK£846.1m-UK£278,503,284.4916x-7.6x2.5x
Thu, 06 Mar 2025UK£2.4bUK£843.9m-UK£278,425,192.5118.4x-8.6x2.8x
Sat, 01 Feb 2025UK£2.8bUK£842.1m-UK£295,378,214.4690.8x-9.5x3.3x
Mon, 30 Dec 2024UK£2.5bUK£841.8m-UK£294,367,694.3573.5x-8.6x3x
Wed, 27 Nov 2024UK£2.7bUK£841.2m-UK£295,021,713.8183.2x-9.2x3.2x
Fri, 25 Oct 2024UK£2.9bUK£840.2m-UK£291,952,544.5894.7x-10x3.5x
Sun, 22 Sep 2024UK£2.8bUK£831.9m-UK£310,148,019.9088.2x-8.9x3.3x
Tue, 20 Aug 2024UK£2.6bUK£836.9m-UK£251,113,603.9230.4x-10.5x3.2x
Thu, 18 Jul 2024UK£2.5bUK£837.7m-UK£256,559,244.7229x-9.9x3x
Sat, 15 Jun 2024UK£2.6bUK£835.7m-UK£273,377,481.5729.4x-9.6x3.1x
Mon, 13 May 2024UK£3.0bUK£835.9m-UK£289,863,648.0031.8x-10.2x3.5x
Wed, 10 Apr 2024UK£3.1bUK£902.3m-UK£200,726,131.2929.1x-15.3x3.4x
Fri, 08 Mar 2024UK£3.1bUK£897.5m-UK£203,284,811.1534.7x-15.3x3.5x
Sun, 04 Feb 2024UK£6.4bUK£1.3b-UK£245,773,262.0037.4x-25.9x5x
Tue, 02 Jan 2024UK£6.4bUK£1.3b-UK£245,176,350.0038.8x-26.1x5x
Thu, 30 Nov 2023UK£6.2bUK£1.3b-UK£245,526,715.0035.8x-25.1x4.9x
Sat, 28 Oct 2023UK£6.4bUK£1.3b-UK£253,173,371.0036.9x-25.1x5x
Mon, 25 Sep 2023UK£6.6bUK£1.3b-UK£223,352,067.0023.6x-29.6x5.2x
Wed, 23 Aug 2023UK£6.6bUK£1.3b-UK£207,890,328.0023.6x-31.7x5.2x
Fri, 21 Jul 2023UK£6.9bUK£1.3b-UK£208,469,105.0023.9x-33.2x5.5x
Sun, 18 Jun 2023UK£7.0bUK£1.3b-UK£204,929,275.0023.1x-34.1x5.6x
Price to Earnings Ratio

-34.1x


Total Market Cap: UK£7.0bTotal Earnings: -UK£204,929,275.00Total Revenue: UK£1.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Price to Earnings3Y Average -28.2x202420252026
Current Industry PE
  • Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 11% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-1.01%
Healthcare2.54%
Biotech-2.20%
Biotech-2.20%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
OXB Oxford BiomedicaUK£6.101.7%
+UK£12.1m		83.7%PS4.4x
HEMO Hemogenyx PharmaceuticalsUK£7.716.4%
+UK£3.2m		334.7%PB43.8x
PRTC PureTech HealthUK£1.280.8%
+UK£2.4m		-10.8%PS89.1x
PBX ProBiotix HealthUK£0.0912.5%
+UK£1.6m		9.1%PS5.2x
0KF3 Palatin TechnologiesUS$14.271.9%
+US$480.4k		160.6%PS2x

Latest News

SBTX
UK£0.065
SkinBioTherapeutics
7D
-33.0%
1Y
-63.1%
PRTC
UK£1.28
PureTech Health
7D
0.8%
1Y
-10.8%
New Narrative • Jun 07

Externally Funded Pipeline And Royalty Streams Will Drive Long Term Upside Potential

Catalysts About PureTech Health PureTech Health is a Boston based biotherapeutics company that builds and scales drug programs through a hub and spoke structure that uses externally funded founded entities. What are the underlying business or industry changes driving this perspective?
GNS
UK£21.70
Genus
7D
-4.6%
1Y
7.4%
Narrative Update • Jun 05

GNS: Margin Discipline And Stable P/E Framework Will Drive Medium Term Upside

Genus’s analyst price target holds steady at £37.00 as analysts balance a modestly lower revenue growth outlook with slightly higher profit margin and P/E assumptions following mixed new coverage from JPMorgan and BNP Paribas. Analyst Commentary Recent research coverage has focused on how Genus’s current valuation lines up with its profit potential, with one new initiation from JPMorgan and another neutral initiation helping anchor the £37.00 analyst price target.
HEMO
UK£7.71
Hemogenyx Pharmaceuticals
7D
6.4%
1Y
334.7%
OXB
UK£6.10
Oxford Biomedica
7D
1.7%
1Y
83.7%
Narrative Update • Jun 04

OXB: Future Upside Will Rely On Fast Track And New APAC Agreement

Analysts have nudged their fair value estimate for Oxford Biomedica slightly lower to £8.41, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E. Recent Street research resuming coverage has reinforced the broader analytical focus on the stock.
GENF
UK£0.021
Genflow Biosciences
7D
1.2%
1Y
177.4%
AVCT
UK£0.69
Avacta Group
7D
-2.1%
1Y
95.7%
PBX
UK£0.09
ProBiotix Health
7D
12.5%
1Y
9.1%
VAL
UK£0.0019
ValiRx
7D
3.0%
1Y
-57.7%
COIL
UK£0.10
Coiled Therapeutics
7D
-8.7%
1Y
-41.7%
4BB
UK£5.25
4basebio
7D
-4.1%
1Y
-50.9%
0KF3
US$14.27
Palatin Technologies
7D
1.9%
1Y
160.6%
TCF
UK£0.0024
Theracryf
7D
6.7%
1Y
-5.9%
SCLP
UK£0.19
Scancell Holdings
7D
-16.7%
1Y
89.9%
FARN
UK£0.43
Faron Pharmaceuticals Oy
7D
-8.2%
1Y
-80.9%
BVXP
UK£15.50
Bioventix
7D
-5.5%
1Y
-43.6%